Allostery Enables Transformative Translation through ALC1 Inhibition
Time: 11:00 am
day: Day Two
Details:
- Leveraging allosteric inhibition in the DDR space towards safer therapies
- Demonstrating that the allosteric small molecule ALC1 inhibitor EIS-12656 disrupts chromatin remodeling and exploits vulnerabilities in HR-deficient tumors
- Exceptional preclinical safety with monotherapy efficacy and potentiation of DDR therapies
- Highlighting exceptional preclinical safety with monotherapy efficacy and potentiation of DDR therapies, outlining the drug’s translational potential and Eisbach’s orthogonal DDR approach
